Verrica Pharmaceuticals IncNASDAQ:VRCA
- LAST PRICE1.6694
- TODAY'S CHANGE (%)-0.0106 (-0.6310%)
- Bid / Lots1.6600/ 14
- Ask / Lots1.6700/ 2
- Open / Previous Close1.6900 / 1.6800
- Day Range
- 52 Week Range
- Volume212,744
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRCA |
|---|---|---|
| 09:32 ET | 3294 | 1.69 |
| 09:34 ET | 248 | 1.67 |
| 09:38 ET | 1400 | 1.675 |
| 09:39 ET | 2600 | 1.66 |
| 09:41 ET | 100 | 1.68 |
| 09:43 ET | 869 | 1.6794 |
| 09:48 ET | 100 | 1.68 |
| 09:52 ET | 300 | 1.68 |
| 09:54 ET | 500 | 1.6794 |
| 09:56 ET | 600 | 1.675 |
| 09:57 ET | 1950 | 1.6724 |
| 09:59 ET | 807 | 1.6794 |
| 10:01 ET | 501 | 1.68 |
| 10:06 ET | 394 | 1.69 |
| 10:10 ET | 280 | 1.6998 |
| 10:12 ET | 7086 | 1.69 |
| 10:14 ET | 275 | 1.697 |
| 10:17 ET | 100 | 1.7 |
| 10:19 ET | 100 | 1.7 |
| 10:21 ET | 100 | 1.7 |
| 10:24 ET | 52824 | 1.715 |
| 10:26 ET | 2735 | 1.72 |
| 10:30 ET | 1771 | 1.74 |
| 10:32 ET | 886 | 1.74 |
| 10:33 ET | 15429 | 1.71 |
| 10:35 ET | 200 | 1.72 |
| 10:44 ET | 400 | 1.73 |
| 10:46 ET | 200 | 1.7237 |
| 10:48 ET | 700 | 1.745 |
| 10:51 ET | 745 | 1.74 |
| 10:53 ET | 513 | 1.7394 |
| 10:55 ET | 1250 | 1.735 |
| 10:57 ET | 47205 | 1.715 |
| 11:00 ET | 400 | 1.71 |
| 11:06 ET | 26627 | 1.705 |
| 11:08 ET | 100 | 1.705 |
| 11:09 ET | 1291 | 1.695 |
| 11:15 ET | 200 | 1.69 |
| 11:20 ET | 200 | 1.695 |
| 11:24 ET | 100 | 1.699 |
| 11:26 ET | 457 | 1.695 |
| 11:27 ET | 449 | 1.695 |
| 11:29 ET | 1982 | 1.7 |
| 11:31 ET | 500 | 1.7 |
| 11:33 ET | 300 | 1.7 |
| 11:36 ET | 346 | 1.6994 |
| 11:38 ET | 200 | 1.6958 |
| 11:40 ET | 1300 | 1.69 |
| 11:44 ET | 100 | 1.7 |
| 11:47 ET | 1353 | 1.6998 |
| 11:49 ET | 100 | 1.7 |
| 11:56 ET | 100 | 1.7 |
| 11:58 ET | 105 | 1.695 |
| 12:02 ET | 2161 | 1.68 |
| 12:07 ET | 100 | 1.7 |
| 12:09 ET | 400 | 1.6894 |
| 12:14 ET | 500 | 1.68 |
| 12:16 ET | 3007 | 1.68 |
| 12:18 ET | 400 | 1.68 |
| 12:20 ET | 856 | 1.67 |
| 12:21 ET | 200 | 1.68 |
| 12:23 ET | 151 | 1.6891 |
| 12:30 ET | 100 | 1.69 |
| 12:32 ET | 200 | 1.685 |
| 12:36 ET | 100 | 1.689 |
| 12:38 ET | 100 | 1.679 |
| 12:39 ET | 200 | 1.68 |
| 12:41 ET | 640 | 1.67 |
| 12:43 ET | 100 | 1.68 |
| 12:52 ET | 1019 | 1.6794 |
| 12:57 ET | 100 | 1.675 |
| 12:59 ET | 100 | 1.675 |
| 01:01 ET | 100 | 1.67 |
| 01:06 ET | 100 | 1.675 |
| 01:10 ET | 100 | 1.675 |
| 01:12 ET | 5648 | 1.665 |
| 01:15 ET | 410 | 1.67 |
| 01:19 ET | 100 | 1.665 |
| 01:24 ET | 250 | 1.6694 |
Yesterday
Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA): Grabar Law Office Investigates Claims on Your Behalf, from 6:46AM ET on Thursday Sep 26, 2024 by Dow Jones
6:46AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 20, 2024
Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA), from 9:21AM ET on Friday Sep 20, 2024 by Dow Jones
9:21AM ET on Friday Sep 20, 2024 by Dow Jones
Sep 13, 2024
Sep 5, 2024
Sep 4, 2024
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, from 7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones
7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verrica Pharmaceuticals Inc | 71.7M | -0.9x | --- |
I-Mab | 89.8M | 0.0x | --- |
Bio Essence Corp | 76.0M | -70.4x | --- |
United-Guardian Inc | 71.4M | 21.7x | -9.92% |
Cellectar Biosciences Inc | 68.5M | -0.6x | --- |
Zhong Yuan Bio-Technology Holdings Ltd | 88.2M | 391.4x | --- |
Company Information
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Contact Information
- Headquarters
- 10 N High St Ste 200WEST CHESTER, PA, United States 19380-3014
- Phone
- 484-453-3300
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Ted White
- Chief Financial Officer
- P. Terence Kohler
- General Counsel, Company Secretary, Chief Legal Office
- Christopher Hayes
- Chief Medical Officer
- Gary Goldenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $71.7M |
|---|---|
Revenue (TTM) | $13.9M |
Shares Outstanding | 42.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-1.88 |
Book Value | $0.47 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -581.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
